Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered clinical trials, aiming to enhance the efficiency and compliance of clinical trial management for innovative drug development [1][2] - Since its establishment, Proris has undertaken over 4,200 SMO projects, with 2,538 currently active, and has a workforce of 4,271 employees [2] - The company has served over 960 clinical trial institutions across more than 200 cities in China, benefiting over 420,000 participants and assisting in the approval of over 210 new drugs [2] Financial Performance - Proris has distributed a total of CNY 46.1455 million in cash dividends since its listing, reflecting a commitment to shareholder returns [2] Industry Demand - In 2025, the number of drug clinical trials in China reached 5,173, a year-on-year increase of 6.44%, with 76 innovative drugs approved, marking a 58% increase [3] - China holds approximately 30% of the global new drug pipeline, ranking second worldwide, indicating a vibrant landscape for innovative drug development [3] Market Trends - The total value of innovative drug licensing transactions in China exceeded USD 130 billion in 2025, with over 150 transactions, setting a historical record [3] - The SMO industry is experiencing a trend towards consolidation, with leading firms expanding their client resources and operational capabilities, while smaller firms are gradually exiting the market [4] Client Base - Proris primarily serves multinational pharmaceutical companies, domestic innovative drug firms, and CROs, collaborating with all of the top 10 global pharmaceutical companies as of 2024 [5] Digital Transformation - The company emphasizes the development and application of digital and intelligent technologies as a key strategic focus, aiming to enhance project execution efficiency through a collaborative clinical trial management platform [6] Quality Management - Proris has established a comprehensive quality management system, having undergone 281 inspections by national and provincial authorities, as well as 14 FDA and 5 EMA inspections, with no major findings reported [7][9] - The company maintains over 280 standard operating procedures (SOPs) to ensure compliance and quality in its operations [9]

Core Insights - The textile industry is undergoing a significant transformation driven by technology, with innovations such as temperature-regulating polyester garments highlighting this shift [1][3] - The 8th World Fabric Conference emphasized the need for global textile enterprises to focus on technological innovation to seize opportunities in the restructured value chain [3] Industry Trends - The integration of technology and industry is crucial for high-quality development in textiles, with material innovation, technological iteration, and model upgrades identified as key engines [3] - Research institutions, such as Donghua University, are pivotal in advancing textile technology, showcasing products like artificial blood vessels that enhance medical applications [3][4] Digital Transformation - The introduction of the AI Fabric 2.0 model, which consolidates a database of 300,000 fabric entries and connects over 5,000 enterprises, has improved new product development and supply chain efficiency by over 30% [6] - The textile industry in Shaoxing Keqiao has achieved comprehensive digital transformation, with 12 companies recognized as national smart factories, resulting in an average production efficiency increase of 32.2% and a cost reduction of 18% [6] Market Dynamics - Shaoxing Keqiao, recognized as the "International Textile Capital," has established a complete industrial chain, with the China Light Textile City projected to exceed a total transaction volume of 400 billion yuan in 2024 [7] - The region aims to enhance key technologies in high-performance fibers, bio-based materials, and green dyeing, positioning itself as a leading modern textile pilot base in China [7]

Group 1: Company Overview and Financial Performance - Proris is a data-driven clinical research service provider focused on patient-centered approaches, enhancing the quality and efficiency of clinical trials in China [2] - In 2024, the company achieved operating revenue of CNY 803.73 million, a year-on-year increase of 5.75%, while net profit attributable to shareholders decreased by 21.01% to CNY 106.43 million [2] - For Q1 2025, operating revenue was CNY 176.47 million, a decline of 4.37%, with net profit dropping 67.32% to CNY 7.43 million [2] Group 2: Contract and Project Management - The company signed new contracts worth CNY 1 billion in 2024, with a total contract amount of CNY 1.889 billion by the end of the year, reflecting a 0.38% increase year-on-year [2] - As of March 31, 2025, Proris has undertaken over 3,800 SMO projects, with 2,250 currently in execution, and a total workforce of 4,277 employees [2] Group 3: Shareholder Value and Dividends - In 2024, the total cash dividend amounted to CNY 19.88 million, accounting for 18.68% of the annual net profit [3] - Cumulative cash dividends from 2022 to 2024 reached CNY 40.77 million [3] Group 4: Industry Trends and Challenges - The SMO industry is entering a new development phase, with increasing concentration among leading firms due to enhanced client resources and regulatory support [3] - In 2024, the number of drug clinical trials registered in China reached 4,861, a 15.60% increase from 4,205 in 2023, indicating a robust growth trend in biopharmaceutical R&D [3] Group 5: Cost Management and Operational Efficiency - The decline in Q1 2025 gross margin was attributed to seasonal impacts, increased operational costs from hiring, and regulatory changes [4] - The company is implementing measures to stabilize gross margins, including enhancing internal controls, optimizing organizational structure, and investing in technological innovations [4][5] Group 6: Future Outlook and Strategic Initiatives - The company plans to continue exploring AI and new technologies in clinical trial execution to improve service quality and efficiency [3][4] - Proris is actively engaging in mergers and acquisitions, considering strategic alignment and valuation in its decision-making process [6][7]